AACR 2023 | Activating the TME with MEDI1191, a lipid nanoparticle with mRNA encoding IL-12

Eduardo Castañón, MD, Universidad de Navarra, Pamplona, Spain, describes the rationale behind the development of MEDI1191, a novel lipid nanoparticle-formulated therapy containing mRNA encoding IL-12. The investigational therapy is administered intratumorally, and IL-12 will enhance the innate and adaptive immune systems, where interferon gamma levels will increase and the tumor microenvironment (TME) will consequently be activated. MEDI1191 is additionally being investigated with an anti-PD-L1 checkpoint inhibitor. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.